Expression arrays illuminate a way forward for mantle cell lymphoma  by Evans, William E et al.
100 CANCER CELL : FEBRUARY 2003
Lymphomas and leukemias are generally
initiated by founding translocations that
deregulate the expression of molecules
that control cell cycle progression and dif-
ferentiation. The hallmark of mantle cell
lymphoma (MCL) is the t(11;14) translo-
cation that fuses the immunoglobulin
heavy chain enhancer-promoter to the
cyclin D1 transcription unit, constitutively
activating the cyclin D1 gene (CCND1)
and disrupting the normal regulation of D-
type cyclins by B cell mitogens (see
Figure 1). As in other hematopoietic
malignancies, additional mutations con-
tribute to a multistep process that not only
gives way to overt disease but also deter-
mines therapeutic responses to available
treatments and attendant prospects for
long-term survival.
Rosenwald and coworkers, in this
issue of Cancer Cell (Rosenwald et al.,
2003), describe the use of genomic pro-
filing to examine genes that determine
the notoriously variable survival of MCL
patients. Lymphochip cDNA microarrays
were used to profile gene expression in
101 MCL patients, with an eye toward
distinguishing this disease from other
lymphoma subtypes. Cyclin D1 was
deliberately excluded in order to identify
other discriminatory genes and to apply
molecular diagnosis to a rare subset of
apparent MCL cases (?9%) that lack
cyclin D1 overexpression by PCR analy-
sis. MCL tumor samples with or without
cyclin D1 expression were correctly diag-
nosed based on expression of 42 other
MCL “signature” genes. Interestingly,
some cases that lacked cyclin D1
expression instead produced high levels
of cyclins D2 and D3. Hence, whereas
the putative existence of cyclin D1-nega-
tive MCL has remained controversial,
these results suggest that D1 overex-
pression can be mimicked at least in part
by other D-type cyclins, which presum-
ably drive cell cycle progression in a
similar manner.
To identify gene expression profiles
that predicted the length of patient sur-
vival, a supervised analysis was per-
formed within the 92 MCL cases that
were cyclin D1 positive. This fingered 48
genes whose expression correlated with
survival duration (p < 0.001); all of these
genes were more robustly expressed in
tumors conveying the worst clinical out-
come. Interestingly, a subset of 20 prolif-
eration signature genes was so effective
in forecasting survival duration that inclu-
sion of other genes from the original
cohort of 48 did not further improve the
predictive model. It is curious that no
genes that identified patients with the
shortest survival were underexpressed.
For example, a number of pro-apoptotic
genes were reported to be markedly
downregulated in MCL compared to non-
malignant lymph node tissue (e.g.,
FADD, CASP9, CASP10, RIPK1, DAXX,
PDCD1) (Hofmann et al., 2001), but the
findings of Rosenwald and colleagues
suggest that their reduced activities are
not hallmarks of patients with the worst
prognosis.
MCL is essentially an incurable dis-
ease with most chemotherapy regimens;
success is still measured by prolongation
of survival, but not cure (Barista et al.,
2001). However, there is some evidence
that the intensity of chemotherapy can
influence outcome, with dose-intensive
cytotoxic chemotherapy coupled with
autologous stem cell rescue and total-
body irradiation achieving 4-year
disease-free survival >70% in patients
under 66 years of age (Khouri et al.,
1998). In the current study, neither treat-
ment nor patient age were included as
covariates in the supervised analysis, but
because these patients generally fail
therapy, differences in their clinical man-
agement may not have significantly
biased gene selection. Elucidating the
molecular pathogenesis of MCL might
ideally identify new targets for the devel-
opment of more effective agents. Profiling
strategies should also help to assess
effects of new agents on genes whose
expression predicts treatment outcome,
thereby serving as a useful tool for drug
development and target validation.
Among patients with MCL, the
majority of genes that predicted poor
long-term survival were those that are
expressed at higher levels in dividing
cells than in quiescent cells.This prolifer-
ation signature correlated directly with
increased tumor S phase fractions and
mitotic indices and inversely with patient
survival. Intriguingly, the proliferation sig-
nature segregated different patient sub-
groups with survival times ranging from
less than one year to almost seven
years. Expression of cyclin D1 was high-
er in groups with a relatively poor prog-
nosis, in part due to the preferential
production of alternatively spliced, short
cyclin D1 mRNA isoforms that exhibit
increased stability. Whereas such splice
variants cannot be readily discriminated
with most cDNA microarrays (e.g.,
Lymphochip), oligonucleotide arrays can
easily be designed to determine the
expression level of specific D1 splice
variants, thereby offering further insights
into the pathogenesis of MCL.
Deletions of the INK4a/ARF locus
(CDKN2a) were detected in about 20% of
MCL cases that had a relatively poor
prognosis. This locus encodes two dis-
tinct tumor suppressors.The p16INK4a pro-
tein is an inhibitor of the cyclin
D-dependent kinases Cdk4 and Cdk6,
preventing their ability to phosphorylate
and inactivate the growth-suppressive
retinoblastoma protein (RB). The human
p14ARF protein, encoded in part from an
alternative reading frame (from which it
gets its name) of the INK4a locus, inhibits
the p53 negative regulator, HDM2, to
induce a p53-dependent transcriptional
program (see Figure 1). Hence, deletion
of INK4a/ARF in MCL should compro-
mise the tumor-suppressive functions of
both RB and p53. Because INK4a/ARF
deletion and cyclin D1 overexpression
were observed to independently con-
tribute to reduced patient survival, these
events must cooperate in some way to
increase MCL proliferation. How does
this work?
Cyclin D-dependent kinases pro-
mote S phase entry through two mecha-
nisms (Sherr and Roberts, 1999). The
first, now well appreciated, involves inac-
tivation of Rb family proteins by direct
phosphorylation. However, the mitogen-
dependent accumulation of cyclin D-
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Expression arrays illuminate a way forward for mantle cell
lymphoma
Analysis of gene expression profiles in mantle cell lymphomas (MCL) has identified a relatively small group of genes that dis-
criminate MCL from other lymphoma subtypes; a cohort of twenty “proliferation signature” genes predicts patient survival.
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dependent kinases also sequesters a
second class of Cdk inhibitory molecules
(p27Kip1 and p21Cip1) into higher order
complexes, thereby preventing these
“Cip/Kip” proteins from inhibiting the
activity of cyclin E- and A-dependent
Cdk2. The catalytic and stoichiometric
activities of cyclin D-dependent kinas-
es—namely, RB phosphorylation and
titration of Cip/Kip proteins, respective-
ly—work hand in hand to stimulate entry
of quiescent cells into S phase. By
disrupting cyclin D1-Cdk4 complexes,
p16INK4a not only inhibits cyclin D-depen-
dent kinase activity but also mobilizes
previously sequestered Cip/Kip proteins,
inhibiting Cdk2 and leading to efficient
cell cycle arrest. One possibility, then, is
that loss of p16INK4a and overexpression
of cyclin D1 cooperate to maintain an
increased fraction of MCL tumor cells in
cycle. This model suggests that progres-
sive increases in the levels of cyclin D-
dependent kinase activity, whether due
to cyclin D1 overexpression or to p16INK4a
loss, determine the probability at which
tumor cells enter S phase and subse-
quently divide.
If this is correct, we might expect that
INK4a point mutations or silencing, which
characteristically inactivate p16INK4a in
many other tumor types, would also
occur in MCLs. Yet, deletions of INK4a,
which also affect ARF, are the hallmarks
of this disease. Minimally, this suggests
that loss of p14ARF may contribute to a
poor prognosis in MCL, presumably by
limiting the activity of p53. In general,
ARF is induced by oncogenes and, by
activating p53, it diverts incipient cancer
cells to undergo p53-dependent fates,
such as cell cycle arrest or apoptosis.
Loss of ARF eliminates this cell-
autonomous tumor surveillance mecha-
nism and allows activated oncogenes,
such as oncogenic Ras or Myc, or possi-
bly cyclin D1, to function unopposed in
driving cell cycle progression. If ARF loss
contributes to MCL, we might not expect
to find p53 mutations in those tumors that
sustain an ARF deletion. However, a few
MCL cases had deletions of both the
INK4a/ARF and p53 loci, raising the pos-
sibility that p53 loss provides yet addition-
al selective advantages. In mouse B cell
lymphomas driven by Myc overexpres-
sion, loss of ARF accelerates disease
progression by primarily limiting Myc-
induced apoptosis, whereas loss of
INK4a disables a cytostatic response to
chemotherapeutic agents. Intriguingly,
loss of p53 cancels both tumor-protective
responses and connotes the worst over-
all outcome (Schmitt et al., 2002).
Regardless of mechanism, a clear
prediction from this work is that inhibitors
of cyclin D1 function (reviewed in
Senderowicz, 2001) should prolong the
life of patients with MCL. However, inter-
fering with cyclin D1-dependent kinase
activity (for example, with a small
molecule Cdk4 inhibitor) might not be
sufficient to arrest disease if the stoichio-
metric activity of cyclin D1-Cdk4 com-
plexes in sequestering Cip/Kip proteins
plays a prominent role. Rather, the ideal
drug would be a p16INK4a-mimetic—a
molecule that disrupts cyclin D1-Cdk4
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Figure 1. Cell cycle control in normal and malignant B cells
Resting B cells (A) do not synthesize D-type cyclins, and cyclin E-Cdk2 complexes are held in an inactive form by p27Kip1. B cell mitogens induce
synthesis of D-type cyclins (B) with cyclins D2 and D3 predominating over D1. Assembly of D-type cyclins with Cdk4 (or Cdk6, not shown)
sequesters p27Kip1 and facilitates activation of cyclin E-Cdk2. Both Cdks phosphorylate and inactivate Rb family proteins, triggering entry into S
phase. In MCL cells bearing the t(11;14) (C), cyclin D1 is overproduced and drives S phase entry. In the early stages of disease, development of
lymphoma is likely held in check by the two products of the INK4a/ARF locus, which antagonize cyclin D1-Cdk4 kinase activity and activate p53
(depicted in the box at bottom). Deletion of the INK4a/ARF locus in MCL cancels these checkpoint responses and connotes a poor prognosis.
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complexes and releases bound Cip/Kip
proteins. Agents acting “upstream” (such
as inhibitors of Ras, Raf, and PI3 kinas-
es) can prevent the induction of cyclin
D1, limit its stability, or interfere with its
assembly with Cdks, and these might
prove efficacious. The ultimate goal must
be to translate these important new
molecular insights into more effective
treatment of MCL; until then, we will con-
tinue to measure success as extended
survival and not cure.
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The c-Jun protein is a component of
transcription factor AP-1 (Angel and
Karin, 1991), encoded by the c-jun gene
(using mouse gene terminology), the
cellular homolog of the retroviral v-jun
oncogene (Vogt, 2001). The discovery
fifteen years ago that c-Jun together
with c-Fos is a component of AP-1, a
transcription factor implicated in the
induction of gene transcription by phor-
bol ester tumor promoters (Angel et al.,
1987), generated a great deal of excite-
ment at the time. For once it suggested a
biochemical function for c-Jun being one
of the first sequence-specific transcrip-
tion factors found to be encoded by a
proto-oncogene. Even more importantly,
it suggested that the putative pro-onco-
genic function of c-Jun is due to its func-
tion at the receiving end of a signal
transduction pathway that mediates
gene induction by phorbol esters and
other tumor promoters. This discovery
also provided a molecular mechanism
and an explanation for tumor promotion,
suggesting that tumor promoters are
chemical and physical agents that can
activate signaling pathways that stimu-
late the activity of transcription factors
that regulate the expression of genes
involved in cell proliferation and neo-
plastic trasformation. This hypothesis
implicated that chronic elevation of c-
Jun’s expression or activity as brought
about by tumor promoters should lead to
oncogenic transformation. However,
direct genetic evidence in favor of this
hypothesis has been lacking. Unlike
other mammalian proto-oncogenes,
mutations in the c-jun locus have not
been found in human or murine cancers
and overexpression of the normal c-Jun
protein does not readily result in trans-
formation of rodent fibroblasts (Shaulian
and Karin, 2002). This important defi-
ciency has finally been rectified. Eferl et
al. report in the recent issue of Cell that
a targeted disruption of the c-jun gene in
mouse hepatocytes does not interfere
with normal function, but prevents the
emergence of hepatocellular carcino-
mas in response to a classical model of
tumor initiation-tumor promotion (Eferl
et al., 2003). These results not only
prove that c-Jun is a critical component
of the carcinogenic mechanism but also
suggest that c-Jun antagonists may be
used in chemoprevention of liver cancer,
a significant health problem in certain
parts of the world.
The acute or chronic loss of hepatic
function caused by alcohol, viral infection,
or other hepatotoxic drugs can result in
severe illness such as fulminant hepatitis,
or cirrhosis, and greatly increases the risk
for eventual development of hepatocellu-
lar carcinoma (Okuda, 2000). Chronic
infections with the hepatitis B virus (HBV)
and the hepatitis C virus (HCV) represent
major risk factors for hepatocellular carci-
noma (Okuda, 2000). AP-1 was reported
to be activated in both hepatocellular car-
cinoma and chronic hepatitis (Liu et al.,
2002). In vitro studies using liver-derived
cell lines have demonstrated rapid activa-
tion of AP-1 by HBV or HCV proteins
(Kato et al., 2000). Thus, there had been
ample reasons to suspect the involve-
ment of c-Jun or other AP-1 proteins in
liver cancer.
In addition to c-Jun and c-Fos, AP-1
transcription factors are composed of
homo- and heterodimers of basic region-
leucine zipper (bZIP) proteins that belong
to the Jun (c-Jun, JunB, and JunD) and
Fos (c-Fos, FosB, Fra-1, and Fra-2) sub-
families, all of which recognize the AP-1
Oncogene at last—c-Jun promotes liver cancer in mice
c-Jun, a component of transcription factor AP-1, has been known to play an important role in the control of cell prolifera-
tion. It was also suspected to be a critical mediator of tumor promotion. In a recent paper in Cell, Eferl et al. have now pro-
vided conclusive evidence that c-Jun expression is critical for induction of liver cancer by a classical protocol of tumor
initiation—tumor promotion.
